These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 19147502

  • 1. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
    Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, Gatti M, Bajetto A, Porcile C, Barbieri F, Favoni RE, Lo Casto M, Zona G, Spaziante R, Florio T, Corte G.
    J Biol Chem; 2009 Mar 13; 284(11):7138-48. PubMed ID: 19147502
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.
    Int J Cancer; 2008 Dec 15; 123(12):2939-49. PubMed ID: 18803287
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P, Howley R, Doolan P, Clarke C, Madden SF, Clynes M, Farrell M, Amberger-Murphy V.
    Exp Cell Res; 2012 Mar 10; 318(5):641-52. PubMed ID: 22285130
    [Abstract] [Full Text] [Related]

  • 6. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 7. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
    Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):e43-52. PubMed ID: 22516386
    [Abstract] [Full Text] [Related]

  • 8. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.
    Cancer Res; 2011 Dec 01; 71(23):7198-206. PubMed ID: 21987724
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
    Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I.
    Cancer Sci; 2006 Feb 01; 97(2):155-62. PubMed ID: 16441427
    [Abstract] [Full Text] [Related]

  • 11. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
    Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, Mutti L, Moro L.
    PLoS One; 2010 Nov 29; 5(11):e14110. PubMed ID: 21124760
    [Abstract] [Full Text] [Related]

  • 12. The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
    Fujishiro Y, Tonogi M, Ochiai H, Matsuzaka K, Yamane GY, Azuma T.
    Int J Oncol; 2012 Jul 29; 41(1):362-8. PubMed ID: 22576692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, Chiu PC, Huang WP, Wang YN, Chen CH, Chang WC, Chang WC, Chen AJ, Tsai CH, Hung MC.
    J Biol Chem; 2011 Jun 10; 286(23):20558-68. PubMed ID: 21487020
    [Abstract] [Full Text] [Related]

  • 15. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 01; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 17. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
    Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, Qin JZ, Liu XX, Liu YN, Zhang XY, Li P, Han S, Liu KY, Zhang JM, He QH, Shen L.
    CNS Neurosci Ther; 2013 Jul 01; 19(7):494-502. PubMed ID: 23575351
    [Abstract] [Full Text] [Related]

  • 18. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
    Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.
    Cancer Discov; 2012 May 01; 2(5):458-71. PubMed ID: 22588883
    [Abstract] [Full Text] [Related]

  • 19. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.
    Clin Exp Pharmacol Physiol; 2013 Jan 01; 40(1):13-21. PubMed ID: 23110505
    [Abstract] [Full Text] [Related]

  • 20. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
    Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.
    PLoS Med; 2005 Nov 01; 2(11):e313. PubMed ID: 16187797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.